Prostatic carcinoma metastatic to choroid

J. PAUL DIECKERT and BRIAN B. BERGER

From the 1Scott and White Memorial Hospital, Scott, Sherwood and Brindley Foundation, and the
2Division of Ophthalmology, Scott and White Clinic, Texas A & M University College of Medicine,
Temple, Texas 76508, USA

SUMMARY Metastatic prostatic carcinoma of the choroid became clinically undetectable after
orchiectomy and oestrogen administration. The choroidal tumour rapidly regressed over a 2-
month period and clinically disappeared, with restoration of 6/6 vision from 6/60 and return of
visual field. This dramatic response and lack of complications make hormonal manipulation the
preferred mode of initial therapy in prostatic carcinoma metastatic to the choroid.

In 1872 Perls reported the first case of carcinoma metastatic to the choroid.1 Since that time well over
400 cases have been reported.2,3 The predominant sources of metastatic carcinoma to the choroid have
been lung in men and breast in women.2 There have been at least 7 reported cases of prostatic carcinoma
metastatic to the choroid.2,4-9

This report describes a case of prostatic carcinoma metastatic to the choroid in which hormonal therapy
causéd complete clinical regression of the metastasis and full return of visual function. To our knowledge
this response has not been previously reported with a choroidal metastasis from prostatic carcinoma.

Case report

A 54-year-old white male was referred to the Scott and White Clinic for evaluation of decreased vision in
his left eye of 4 months’ duration. His past medical history consisted of diabetes mellitus for two years
treated with 10 units of insulin per day and chronic hypertension treated with a combination of reserpine,
hydralazine, and hydrochlorothiazide. Review of systems revealed impotence, sacral pain, and urinary
frequency.

Eye examination revealed a best corrected visual acuity of 6/6 right eye and 6/60 left eye. The positive
physical findings were confined to the left fundus. A nonpigmented choroidal tumour was present
temporally extending into the fovea and approxi-
mately 9 mm vertically by 6 mm horizontally (Fig.
1A). Very minimal subretinal fluid was associated
with it. B scan ultrasonography showed a choroidal
tumour with moderate internal reflectivity, no
choroidal excavation, and about 5 mm in thickness
(Fig. 2). Fluorescein angiography showed widespread
hyperfluorescence due to defects of the retinal
pigment epithelium but no distinct tumour circulation
(Fig. 3A). Goldmann perimetry demonstrated an
absolute visual field defect nasally in the left eye (Fig.
4A).

General physical examination was unremarkable
with the exception of an enlarged, nodular prostate.
On laboratory testing an acid phosphatase level of 21
IU/l (normal 0–6) and a prostatic fraction of 13 IU/l
(normal 0–6) was noted. Chest x-rays revealed numerous nodular densities compatible with
metastatic lesions. Prostatic needle biopsy confirmed
grade 3 moderately well differentiated adenocarcinoma of the prostate (Fig. 5). No lesions were
demonstrable on computerised axial tomography of
the head. Bone scan revealed abnormal uptake in the
axial skeleton, ribs, and entire left orbit (Fig. 6).

Over a period of a week the patient was treated
with palliative cobalt-60 irradiation to painful bony
lesions, transurethral resection of the prostate, and
bilateral orchidectomy. In addition he was started on
diethylstilboesterol 3 mg per day. Within 2 weeks the
choroidal tumour had decreased to one-half its
original size (Fig. 1B) and vision had improved to
6/15. In 4 weeks visual acuity improved to 6/6, and
within 2 months the tumour was not clinically
apparent (Fig. 1C). The visual field became almost
Prostatic carcinoma metastatic to choroid

full (Fig. 4B) and the acid phosphatase level normal. The only evidence of the previous tumour was atrophy of the retinal pigment epithelium, which was prominent on fluorescein angiography (Fig. 3B). After 12 months of follow-up he is free of any ocular recurrence.

Discussion

Greenwood and Southard reported the first case of prostatic carcinoma metastatic to the choroid in 1903. Since then at least 4 cases have been reported in the American and 3 in the European literature. Several large series of metastatic choroidal tumours from various sites have included previously reported cases.

The usual presenting symptom is decreasing visual acuity secondary to serous retinal detachment from choroidal metastasis; however, concurrent choroidal and optic nerve involvement has been reported. Some of the reported cases received enucleation for relief of pain or diagnostic purposes. Others died
Fig. 2  Combined A and B ultrasonogram showing tumour 5 mm in thickness with moderate internal reflectivity.

Fig. 3  (A) Fluorescein angiography showing hyperfluorescence due to window defects prior to treatment. (B) More extensive atrophy of the retinal pigment epithelium after tumour regression.

before any ocular therapy was attempted. None of the reported cases were managed with hormonal manipulation.

Prostatic carcinoma metastatic to the choroid accounts for only 1-7% of all choroidal metastases in the series by Hart. The incidence of choroidal metastases of all types is unknown, since no prospective studies have been done to answer this question. In a retrospective study only 6 patients with choroidal metastases were found out of 8712 patients with neoplasms of all types.

The percentage of ocular metastases in those patients with prostatic carcinoma is also small. Many series do not even mention ocular metastases. One early series of 100 necropsies of patients with metastatic carcinoma of prostatic origin included only
one case of ocular involvement, the same case as Greenwood and Southard reported.10
Prostatic carcinoma can metastasise to the choroid by at least 2 routes. In those individuals with metastases in the lungs, as in our case, tumour emboli pass via the pulmonary circulation into the heart and aorta. They subsequently travel up the carotid arteries to the ophthalmic artery and into the ciliary vessels and uveal tract.
If no pulmonary lesions are present, prostatic or vertebral lesions may seed into Batson’s plexus. In this way tumour emboli can bypass the pulmonary circulation and reach the cranial venous sinuses. From the cranial venous sinuses the emboli can reach the ophthalmic veins and vortex veins. Batson’s plexus is valveless, and many reversals of flow are said to occur with changes in venous pressure secondary to changes in body posture and Valsalva manoeuvres.15
This case is unique in that all the patient’s ocular symptoms and signs resolved with hormonal therapy. The physiological basis for hormonal therapy of metastatic prostatic tumours is well outlined by

Fig. 4 (A) Goldmann visual field of left eye at time of presentation. (B) After 4 months of therapy.
Walsh and is beyond the scope of this report.\textsuperscript{16} Choroidal tumours derived from breast carcinoma have been shown to be responsive to hormonal manipulation.\textsuperscript{17,18} The time course of resolution of ocular lesions was 2 to 3 months in these cases. A similar time course was noted in our case. Exophthalmos secondary to prostatic carcinoma to the orbit has also been shown to resolve with hormonal manipulation over a similar time course.\textsuperscript{19–21}

According to Reese the goals of treating metastatic tumours to the choroid are preservation of vision and prevention of pain.\textsuperscript{22–24} Carcinoma metastatic to the choroid has a poor prognosis, with life expectancy measured in months.\textsuperscript{2,24} Radiotherapy has been the treatment of choice, since it may cause tumour regression and restoration of vision over 4 to 8 weeks.\textsuperscript{3,25,26} Since hormonal manipulation is commonly used to treat widespread metastases from prostatic carcinoma, the effect of this form of therapy on choroidal metastases from the prostate should be observed before recommending radiation therapy.

References

Prostatic carcinoma metastatic to choroid

Prostatic carcinoma metastatic to choroid.

J. P. Dieckert and B. B. Berger

doi: 10.1136/bjo.66.4.234